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Abstract
Objective. SLE is characterized by relapses and remissions. We aimed to describe the frequency, type and time
to flare in a cohort of SLE patients.
Methods. SLE patients with one or more ‘A’ or ‘B’ BILAG-2004 systems meeting flare criteria (‘new’ or ‘worse’
items) and requiring an increase in immunosuppression were recruited from nine UK centres and assessed at base-
line and monthly for 9 months. Subsequent flares were defined as: severe (any ‘A’ irrespective of number of ‘B’
flares), moderate (two or more ‘B’ without any ‘A’ flares) and mild (one ‘B’).
Results. Of the 100 patients, 94% were female, 61% White Caucasians, mean age (S.D.) was 40.7 years (12.7) and
mean disease duration (S.D.) was 9.3 years (8.1). A total of 195 flares re-occurred in 76 patients over 781 monthly
assessments (flare rate of 0.25/patient-month). There were 37 severe flares, 32 moderate flares and 126 mild flares.
By 1 month, 22% had a mild/moderate/severe flare and 22% had a severe flare by 7 months. The median time to
any ‘A’ or ‘B’ flare was 4 months. Severe/moderate flares tended to be in the system(s) affected at baseline,
whereas mild flares could affect any system.
Conclusion. . In a population with active SLE we observed an ongoing rate of flares from early in the follow-up
period with moderate–severe flares being due to an inability to fully control the disease. This real-world population
study demonstrates the limitations of current treatments and provides a useful reference population from which to
inform future clinical trial design.
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Introduction
SLE is a major autoimmune multi-system rheumatic dis-
ease that is most common in women during the child-
bearing years [1]. It can affect any organ system and the
disease varies in its clinical manifestations and severity
between individuals. For most patients the disease is
characterized by unpredictable relapses (flares) and
remissions [2]. In recent years, mortality rates have
improved [3] but there is still no cure, and flares of dis-
ease, infection and damage all continue to contribute to
excess morbidity and mortality [4].
Flare is defined by International Consensus as ‘a
measurable increase in disease activity in one or more
organ systems involving new or worse clinical signs and
symptoms and/or laboratory measurements. It must be
considered clinically significant by the assessor and
usually there would be at least consideration of change
or an increase in treatment’ [5]. Flares are assessed
using various validated disease activity measures.
However, there is no standardized definition of a meas-
urable increase in disease activity. The three main dis-
ease activity indices currently used in clinical trials are
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Assessment Trial-SLEDAI (SELENA-SLEDAI) [6, 7],
SLEDAI-2K [8] and the BILAG-2004 index [9]. For the
SLEDAI and its derivatives, items are scored numerically
and a numerical increase of at least three compared
with the previous assessment constitutes a flare [5, 10,
11]. For the BILAG-2004 index, the presence of an item
that is ‘worse’ or ‘new’ constitutes a flare [12–14].
Flares have been associated with more hospitaliza-
tions [15] and more organ and system damage, which in
turn can lead to poorer prognosis and increased mortal-
ity [16–18]. In addition, the prolonged use of CS in the
presence of persistence of disease or during flares can
contribute to damage [19]. Flares, damage and pro-
longed use of CS can contribute to poor health-related
quality of life [20–23]. Therefore, flare prevention is an
important treatment goal in patient management.
Understanding the pattern of flares in SLE patients
would be informative not only in the day to day manage-
ment of these patients, but also in the interpretation of
clinical trials of new medications where frequency and
type of flares are included as outcome measures. This
study describes the flare rates and types of flares in a
prospective observational multicentre study of patients
with active SLE after treatment of a flare.
Methods
The study was granted Multicentre Research Ethics
Committee (MREC 02/5/035) approval and participants
from the collaborating centres gave written informed
consent. The collaborating rheumatology units were UK
centres with an interest in SLE as part of the BILAG:
Bangor, Birmingham (two centres), Blackburn, University
College London, Nottingham, Manchester, Doncaster
and Sheffield.
The inclusion and exclusion criteria of the patients
recruited, and the demographic and clinical data col-
lected have been detailed previously in the longitudinal
study to determine the sensitivity to change of the
LupusQoL [24]. Patients were eligible to be included in
the study if they had a flare of SLE requiring specific
treatment. For this study, flare was defined as a signifi-
cant increase in disease activity resulting in a BILAG-
2004 index ‘A’ or ‘B’ score based on manifestation(s) that
are ‘new’ or ‘worse’ [9, 13, 14, 25]. In addition, the flare
definition for this study required patients to have an in-
crease in therapy defined as one or more of the following:
an increase of oral prednisolone to 20 mg/day, introduc-
tion of MTX, parenteral methylprednisolone, and/or other
immunosuppressive therapy (e.g. CYC, rituximab). These
patients were followed up monthly for 9 months and the
BILAG-2004 disease activity index was assessed at each
time point. For the purposes of this study, subsequent
flares were defined as: severe (‘A’ flare/s irrespective of
number of ‘B’ flares), moderate (two or more ‘B’ flares
without any ‘A’ flares) and mild (one ‘B’ flare). We calcu-
lated the total numerical BILAG-2004 score at baseline
where A¼12, B¼ 8, C¼1 for each system [25].
Statistical methods
Patient data were summarized using the following descrip-
tive statistics; means (S.D.), medians (interquartile ranges)
and/or frequency counts. Flare rates were expressed as
the number of flares per patient-month. Time to flare was
also estimated using the Kaplan–Meier method.
Results
Patient characteristics
We recruited 100 patients with a mean (S.D.) age and
disease duration of 40.7 (12.7) years and 9.3 (8.1) years,
respectively. The study population consisted of 94%
females, 62.6% White Caucasians, 15.2% south Asians,
8.1% Black Caribbean, 4% Black Africans, 5% mixed
and 1% Chinese. At baseline (initial flare), the median
(range) numerical BILAG-2004 score was 14 (10–21).
The baseline characteristics are summarized in Table 1.
Table 2 show the medications the patients were on at
recruitment including for the treatment of the flare.
Flare rates and types of flares
During follow-up, 195 flares occurred in 76 patients over
781 months of follow-up (0.25 flares per patient-month).
Table 3 summarizes the flare severity category in these
patients: there were 37 severe flares in 22 patients, 32
moderate flares in 19 patients and 126 mild flares in 67
patients. Twenty-nine patients had more than one type of
flare in the 9 months: 12 had severe and mild flares, 14
had moderate and mild flares and three patients had all
three types of flares (severe, moderate and mild). Twenty-
four (24%) patients did not experience any ‘A’ or ‘B’ flares.
The median time to any ‘A’ or ‘B’ flare was 4 months.
By 1 month, 22% of all patients had a mild/moderate/
severe flare; 22% of all patients had a moderate/severe
flare by 3 months; and 22% of all patients had a severe
flare by 7 months. Fig. 1 shows the time to the first mild/
Rheumatology key messages
. In this observational study, SLE patients flare early on in the follow-up period.
. The median time to any ‘A’ or ‘B’ flare (BILAG-2004 index) was 4 months.
. This real-world population study provides a useful reference which can inform future clinical trial design.
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moderate/severe flare (Curve 1), moderate/severe flare
(Curve 2) and severe flare (Curve 3).
The BILAG-2004 system(s) that had ‘A’ and/or ‘B’
flares at baseline were as follows: musculoskeletal
(39.4%), mucocutaneous (21.8%), cardiorespiratory
(13.5%), renal (11.8%), constitutional (7.7%), neuro-
psychiatric (2.4%), gastrointestinal (2.4%) and ophthal-
mic (1.2%). The systems affected at baseline were
compared with those affected at the time of the first se-
vere, moderate and mild flares. Severe (13.6% discord-
ant) and moderate (5.3% discordant) flares tended to be
in the same system(s) affected at baseline, whereas mild
flares were more likely to affect any system (34.3% dis-
cordant) (Table 4).
Discussion
This multicentre prospective observational study cap-
tured the frequency of subsequent flare in a population
entering the study at the time of moderate or severe
flare. Using the BILAG-2004 index, we have described
the pattern of flares in patients with SLE who were
treated for severe or moderate flares over a 9-month
period. These patients were followed monthly and were
treated with various medications. We found that 76% of
patients had a subsequent flare and the flare rate was
0.25/patient-month, of which 19% were severe, 16%
moderate and the rest were mild flares. The flares were
predominantly in the original organ system, demonstrat-
ing the inadequacy of current treatment to control dis-
ease and to prevent further flares that increase the risk
of future organ damage.
There are only a small number of studies in the litera-
ture exploring incidence of flare in SLE as an outcome.
These studies are difficult to compare with our study or
with each other for the following reasons; different study
populations and various methodological differences
including study design (observational/interventional),
duration of study, outcome measures employed and
flare definitions. The challenges of making cross study
comparisons are illustrated in supplementary Table S1,
available at Rheumatology online, in studies that have
used the BILAG index as a disease activity measure and
a similar definition of flare [26–31].
Our study presents real-world data on patterns of flares
and flare frequency in SLE patients in the UK after treat-
ment of a severe or moderate flare with conventional ther-
apy [32]. Thus, the patients included in this study are
typical of those that meet the eligibility criteria (inclusion
criteria of moderate–severe flares) for an interventional
study. The frequency (monthly) of patient review has gen-
erated a wealth of data not only on the natural history of
subsequent flares after standard treatment (flare rates),
but also on the types (severity and system involvement) of
TABLE 1 Patient baseline demographic and clinical characteristics [n (%) unless stated]
Females 94 (94)
Mean (S.D.) age/disease duration (years) 40.7 (12.7)/9.3 (8.1)
Ethnic distribution (n¼99)
White (British, Irish) 62 (63)
Black (Caribbean, African) 12 (12)
Asian (Indian, Pakistani, Bangladeshi) 14 (14)
Chinese 1 (1)
Other Asian 3 (3)
Mixed 7 (7)
Baseline clinical characteristics (ACR criteria)
Malar rash 43 (43)
Photosensitivity rash 47 (47)
Discoid rash 12 (12)
Mouth ulcers 47 (47)
Arthritis 92 (91)
Serositis 45 (45)
Renal disease 21 (21)
CNS disease 8 (8)
Haematological disease 73 (72)
Positive ANA 96 (95)
Positive dsDNA, Sm or Antiphospholipid antibodies (APA) antibodies 80 (79)
BILAG-2004 index numerical score, median (range) 14 (10–21)
TABLE 2 Treatment at start of the study (for treatment of
flares and background medications at recruitment)








Steroids (oral or i.v. or i.m.) 87
aMost patients were on two medications and some were
on three medications.
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TABLE 3 Type and frequency of flares
Types of flares (using BILAG-2004 index) per patient (n 5 100) Number of patients (n)
Severe (any ‘A’ flares irrespective of ‘B’ flares)
Any severe flare 22
Only one severe flare 15
Multiple severe flares 7
Severe flares only (without moderate/mild flares) 7
Severe and moderate flares only 0
Severe and moderate and mild flares 3
Severe and mild flares only 12
Moderate (two or more ‘B’ flares without any ‘A’ flares)
Any moderate flare 19
Only one moderate flare 12
Multiple moderate flare 7
Moderate flares only (without severe/mild flares) 2
Moderate and severe flares only 0
Moderate and severe and mild flares 3
Moderate and mild flares only 14
Mild (one ‘B’ flare)
Any mild flare 67
Only one mild flare 36
Multiple mild flares 31
Mild flares only (without severe/moderate flares) 38
Mild and severe flares only 12
Mild and severe and moderate 3
Mild and moderate flares only 14
No flares (no ‘A’ or ‘B’ scores due to items new or worse)
Patients with no ‘A’ or ‘B’ scores 24
FIG. 1 Time to first flare with regards to type of flares (mild, moderate or severe)
Curve 1: time to first mild/moderate/severe flare. Curve 2: time to first moderate/severe flare. Curve 3: time to first se-
vere flare.
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flares. Thus, the findings of our study may be of relevance
to inform the design of interventional studies.
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